PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 21, 2026ESMO Open2 citationsOpen Access

LBA1 Ceralasertib (C) + durvalumab (D) in patients (pts) with locally advanced (LA) or metastatic (m) NSCLC who progressed on or after anti-PD-(L)1 and platinum-based chemotherapy (CT): Results from LATIFY

BBB. BesseEFE. FelipBCB.C. Cho

Key Points

  • The research aims to evaluate the efficacy of ceralasertib combined with durvalumab in patients with advanced non-small cell lung cancer.
  • Investigated patients with locally advanced or metastatic NSCLC
  • Participants previously treated with anti-PD-(L)1 and platinum-based chemotherapy
  • Assessment of overall survival and safety profiles after treatment
  • No statistically significant improvement in overall survival compared to docetaxel
  • Ceralasertib and durvalumab exhibited manageable toxicity
  • Adverse events were consistent with known safety profiles of individual agents

Abstract

5 (0.4-31.9) 3.8 (0-31.7)3.0 (0.3-27.6)CI, confidence interval; HR, hazard ratio; mo, months.Conclusions: C+D did not demonstrate a statistically significant improvement in OS vs docetaxel.C+D had manageable toxicity and AEs were consistent with the known safety profiles of each agent.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Besse et al. (2026) studied this question.

synapsesocial.com/papers/69be34d16e48c4981c67303ehttps://doi.org/10.1016/j.esmoop.2026.106957
Ask AI
Helpful
Bookmark
Share
View Full Paper